Dynavax Technologies Corporation
2929 Seventh Street
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. We develop cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.
HEPLISAV-B™ - Our Lead Product Candidate
HEPLISAV-B is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response providing improved protection against hepatitis B. The ongoing Phase 3 study is designed to provide a sufficiently-sized safety database for the FDA to complete its review of Dynavax's biologics license application.
SD-101 - Cancer Immunotherapy
We are utilizing our expertise in TLR biology to develop treatments for cancer by focusing the power of the body’s immune response on cancer cells through optimal stimulation of TLR9 signaling. Our lead cancer immunotherapy product candidate, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells (PDC) to antigen-presenting cells. Our approach provides multiple mechanisms for attacking the tumors along with developing immune memory associated with antigens found in the tumor.
TLR signaling plays an important role in a variety of immune-mediated diseases including asthma and certain autoimmune and inflammatory diseases. Through modulation of TLR signaling we are developing product candidates that can inhibit stimulation of TLRs that lead to autoimmune and inflammatory diseases as well using TLR agonist to rebalance the Th1 versus Th2 response in asthma